
Anders Sonnerborg

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6662140/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Integrase strand transfer inhibitor use and cancer incidence in a large cohort setting. Open Forum Infectious Diseases, 2022, 9, ofac029.	0.9	3
2	All-Cause Mortality and Serious Non-AIDS Events in Adults With Low-level Human Immunodeficiency Virus Viremia During Combination Antiretroviral Therapy: Results From a Swedish Nationwide Observational Study. Clinical Infectious Diseases, 2021, 72, 2079-2086.	5.8	46
3	SARSâ€CoVâ€2â€specific humoral and cellular immunity persists through 9 months irrespective of COVIDâ€19 severity at hospitalisation. Clinical and Translational Immunology, 2021, 10, e1306.	3.8	36
4	High-dimensional profiling reveals phenotypic heterogeneity and disease-specific alterations of granulocytes in COVID-19. Proceedings of the National Academy of Sciences of the United States of America, 2021, 118, .	7.1	52
5	Incidence, treatment and outcome of HIV-associated hematologic malignancies in people living with HIV in Sweden. AIDS Research and Human Retroviruses, 2021, , .	1.1	1
6	Human Immunodeficiency Virus Continuum of Care in 11 European Union Countries at the End of 2016 Overall and by Key Population: Have We Made Progress?. Clinical Infectious Diseases, 2020, 71, 2905-2916.	5.8	16
7	Infectivity of SARS-CoV-2: there Is Something More than D614G?. Journal of Neurolmmune Pharmacology, 2020, 15, 574-577.	4.1	44
8	Innate lymphoid cell composition associates with COVIDâ€19 disease severity. Clinical and Translational Immunology, 2020, 9, e1224.	3.8	56
9	Feasibility of Known RNA Polymerase Inhibitors as Anti-SARS-CoV-2 Drugs. Pathogens, 2020, 9, 320.	2.8	26
10	Virologic and immunologic outcomes of treatment with integrase inhibitors in a real-world setting: The RESPOND cohort consortium. PLoS ONE, 2020, 15, e0243625.	2.5	8
11	Long-Acting Anti-HIV Drugs Targeting HIV-1 Reverse Transcriptase and Integrase. Pharmaceuticals, 2019, 12, 62.	3.8	30
12	Optimal probability weights for estimating causal effects of timeâ€varying treatments with marginal structural Cox models. Statistics in Medicine, 2019, 38, 1891-1902.	1.6	6
13	Prophylaxis and treatment of HIV-1 infection in pregnancy – Swedish Recommendations 2017. Infectious Diseases, 2018, 50, 495-506.	2.8	14
14	The Human Immunodeficiency Virus Continuum of Care in European Union Countries in 2013: Data and Challenges. Clinical Infectious Diseases, 2017, 64, 1644-1656.	5.8	46
15	Six-week follow-up after HIV-1 exposure: a position statement from the Public Health Agency of Sweden and the Swedish Reference Group for Antiviral Therapy. Infectious Diseases, 2016, 48, 93-98.	2.8	7
16	Global Dispersal Pattern of HIV Type 1 Subtype CRF01_AE: A Genetic Trace of Human Mobility Related to Heterosexual Sexual Activities Centralized in Southeast Asia. Journal of Infectious Diseases, 2015, 211, 1735-1744.	4.0	62
17	Efficacy and Safety of Antiretroviral Therapy Initiated One Week after Tuberculosis Therapy in Patients with CD4 Counts < 200 Cells/μL: TB-HAART Study, a Randomized Clinical Trial. PLoS ONE, 2015, 10, e0122587.	2.5	23
18	Long-Term Outcome of Liver Transplantation in HIV-1-Positive Patients: 15-Year Follow-Up. ISRN Transplantation, 2013, 2013, 1-8.	0.2	1

#	Article	IF	CITATIONS
19	5th European HIV Drug Resistance Workshop. Future HIV Therapy, 2007, 1, 141-143.	0.4	3
20	Antiretroviral treatment of HIV infection: Swedish recommendations 2005. Scandinavian Journal of Infectious Diseases, 2006, 38, 86-103.	1.5	7
21	Follow-up of Antiretroviral Treatment in Liver Transplant Recipients with Primary and Chronic HIV Type 1 Infection. AIDS Research and Human Retroviruses, 2003, 19, 13-19.	1.1	13